LianBio

LianBio (LIAN) priced its initial public offering on Nov 2, 2021 at $16.00 per ADS, within its $15.00–$17.00 range, raising $325M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $1.36B. Goldman Sachs was lead-left underwriter, joined by Jefferies, BofA Securities and Raymond James. Ropes & Gray, Travers Thorp Alberga and Zhong Lun advised the company and Cooley and Commerce & Finance advised the underwriters.

LianBio is a biopharmaceutical company developing and commercializing medicines for patients with unmet needs, with an initial focus on in-licensing assets for Greater China and other Asian markets. It partners with biopharmaceutical companies around the world.

Status

IPO

Ticker

LIAN

Exchange

Nasdaq Global Market

Priced

Nov 2, 2021

IPO price

$16.00 per ADS

Price range

$15.00–$17.00

Raised

$325M

Market cap at IPO price

$1.36B

First filed

Oct 1, 2021

Underwriters

Goldman Sachs, Jefferies, BofA Securities and Raymond James

Company counsel

Ropes & Gray, Travers Thorp Alberga and Zhong Lun

Underwriters' counsel

Cooley and Commerce & Finance

Sector

Biotech & pharma

Country / state

NJ

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.